In summary, hepatic IL-32 and CCL20 expression is increased in MASH samples with progressed activity (intense steatosis and moderate-to-severe fibrosis), and enhanced IL-32 expression was found to be related to the PNPLA3 I148M variant. Here, CCL20 is linked to steatosis.